Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833781 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00833781: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00833781 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00833781, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of the study is to find out whether an experimental autologous dendritic cell vaccine is safe, well tolerated, and whether it can strengthen the immune system's response to HIV.
Interventions
- BIOLOGICAL mRNA-transfected autologous dendritic cells
- BIOLOGICAL autologous dendritic cells with no mRNA transfection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-08 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833781
The ClinicalTrials.gov registry entry for NCT00833781 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which mRNA-transfected autologous dendritic cells is the first listed.
NCT00833781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00833781 about?
NCT00833781 is a clinical study titled "A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects". The purpose of the study is to find out whether an experimental autologous dendritic cell vaccine is safe, well tolerated, and whether it can strengthen the immune system's response to HIV.
What is the current status of trial NCT00833781?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2009-08. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00833781?
The interventions under investigation include: mRNA-transfected autologous dendritic cells (BIOLOGICAL), autologous dendritic cells with no mRNA transfection (BIOLOGICAL).
Who is sponsoring clinical trial NCT00833781?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.